Issue of Shares

December 18, 2023
RNS Number : 0685X
Renalytix PLC
18 December 2023

Renalytix plc

("Renalytix" or the "Company")


Issue of Shares


LONDON and SALT LAKE CITY - December 18, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), announces the repayment of $1.06 million of the Company's convertible bond and the interest for the period, further details of which were announced on 31 March 2022. The repayment is being made through the issue of 2,500,000 Ordinary Shares and $600,000 in cash.


After settlement of the repayment, the principal remaining under the convertible bond will be reduced by $1.06 million to $13.78 million.


2,500,000 new ordinary shares of £0.0025 each in the capital of the Company (the "Ordinary Shares") will be issued to settle a portion of the principal and interest.


An application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 2,500,000 new Ordinary Shares to trading on AIM will become effective on, or around, 8am UK time on 21 December 2023 ("Admission"). The new Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.


Total voting rights

Following Admission, the Company will have 99,930,156 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 99,930,156.


For further information, please contact:


Renalytix plc

James McCullough, CEO

Via Walbrook PR


Stifel (Nominated Adviser, Joint Broker)

Tel: 020 7710 7600

Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea



Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Shalin Bhamra


Walbrook PR Limited

Tel: 020 7933 8780 or

Paul McManus / Alice Woodings / Charlotte Edgar

Mob: 07980 541 893 / 07407 804 654 / 07884 664 686  

CapComm Partners

Peter DeNardo

Tel: 415-389-6400 or





About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.